share_log

騰盛博藥-B：有關BRII-179購買協議、技術轉讓補充協議、VBI-1901許可協議、REHOVOT資產購買協議及提供抵押之須予披露交易

BRII-B: DISCLOSEABLE TRANSACTION IN RELATION TO BRII-179 PURCHASE AGREEMENT, TECHNOLOGY TRANSFER SIDE LETTER, VBI-1901 LICENSE AGREEMENT, REHOVOT ASSETS PURCHASE AGREEMENT AND PROVISION OF COLLATERAL

香港交易所 ·  Feb 13 18:59
Summary by Moomoo AI
騰盛博藥-B於2024年2月13日美國東部時間（即香港時間2月14日）宣布，與VBI訂約方達成多項交易，包括BRII-179購買協議、技術轉讓補充協議、VBI-1901許可協議及REHOVOT資產購買協議。該交易涉及全球範圍內BRII-179相關知識產權的永久性購買，以及在亞太地區（不包括日本）開發及商業化VBI-1901的獨家許可。此外，公司將收購與REHOVOT設施相關的資產及負債。作為交易代價，騰盛博藥將發行有抵押承兌票據。這些交易被視為須予披露交易，並須遵守上市規則第14章的通告及公告規定。交易完成後，騰盛博藥將擁有BRII-179及PreHevbri®的全球開發及商業化權利，並透過REHOVOT設施確保產品的臨時供應。公司股東及潛在投資者應謹慎行事，因交易仍須待各相關協議條件達成後方可實施。
騰盛博藥-B於2024年2月13日美國東部時間（即香港時間2月14日）宣布，與VBI訂約方達成多項交易，包括BRII-179購買協議、技術轉讓補充協議、VBI-1901許可協議及REHOVOT資產購買協議。該交易涉及全球範圍內BRII-179相關知識產權的永久性購買，以及在亞太地區（不包括日本）開發及商業化VBI-1901的獨家許可。此外，公司將收購與REHOVOT設施相關的資產及負債。作為交易代價，騰盛博藥將發行有抵押承兌票據。這些交易被視為須予披露交易，並須遵守上市規則第14章的通告及公告規定。交易完成後，騰盛博藥將擁有BRII-179及PreHevbri®的全球開發及商業化權利，並透過REHOVOT設施確保產品的臨時供應。公司股東及潛在投資者應謹慎行事，因交易仍須待各相關協議條件達成後方可實施。
TENSENG PHARMACEUTICALS B-B ANNOUNCED ON FEBRUARY 13, 2024 U.S. EASTERN TIME (I.E. FEBRUARY 14, HONG KONG TIME) THAT IT HAS REACHED A NUMBER OF TRANSACTIONS WITH THE VBI CONTRACTOR, INCLUDING THE BRII-179 PURCHASE AGREEMENT, THE TECHNOLOGY TRANSFER SUPPLEMENTAL AGREEMENT, THE VBI-1901 LICENSE AGREEMENT AND THE REHOVOT ASSET PURCHASE AGREEMENT. The transaction involves the permanent acquisition of BRII-179 related intellectual property rights worldwide, as well as the exclusive license to develop and commercialize VBI-1901 in the Asia-Pacific region (excluding Japan). IN ADDITION, THE COMPANY WILL ACQUIRE ASSETS AND LIABILITIES ASSOCIATED WITH THE REHOVOT FACILITY. As a transaction fee, Tengsheng Pharmaceutical will issue secured promissory notes. These transactions are considered to be disclosable transactions and are subject to the Notices and...Show More
TENSENG PHARMACEUTICALS B-B ANNOUNCED ON FEBRUARY 13, 2024 U.S. EASTERN TIME (I.E. FEBRUARY 14, HONG KONG TIME) THAT IT HAS REACHED A NUMBER OF TRANSACTIONS WITH THE VBI CONTRACTOR, INCLUDING THE BRII-179 PURCHASE AGREEMENT, THE TECHNOLOGY TRANSFER SUPPLEMENTAL AGREEMENT, THE VBI-1901 LICENSE AGREEMENT AND THE REHOVOT ASSET PURCHASE AGREEMENT. The transaction involves the permanent acquisition of BRII-179 related intellectual property rights worldwide, as well as the exclusive license to develop and commercialize VBI-1901 in the Asia-Pacific region (excluding Japan). IN ADDITION, THE COMPANY WILL ACQUIRE ASSETS AND LIABILITIES ASSOCIATED WITH THE REHOVOT FACILITY. As a transaction fee, Tengsheng Pharmaceutical will issue secured promissory notes. These transactions are considered to be disclosable transactions and are subject to the Notices and Notices provided for in Chapter 14 of the Listing Rules. Upon completion of the transaction, Tengshengbo Pharmaceuticals will have the global development and commercialization rights for BRII-179 and PreHEVBRI® and will ensure the provisional supply of the products through the REHOVOT facility. The Company's shareholders and potential investors should exercise caution as the transaction is still subject to completion of the relevant agreement conditions.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more